CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Biogen acquires gene therapy company Nightstar Therapeutics

A UK company that is developing genetic treatments for retinitis pigmentosa and choroideremia has been acquired by a US biotech firm


The UK company behind pioneering genetic treatments for inherited eye disease has been acquired by US biotechnology company, Biogen, for approximately $800 million (£604 million).

Nightstar Therapeutics is developing gene therapies for choroideremia and retinitis pigmentosa in collaboration with Professor Robert MacLaren and other researchers from the University of Oxford.

The announcement follows the acquisition of US-based gene therapy firm Spark Therapeutics Swiss company Roche for $4.8 billion (£3.6 billion).

A gene therapy trial carried out by Nightstar Therapeutics in choroideremia patients resulted in all patients who received the intervention without complications either gaining or maintaining vision in the affected eye over a five-year period.

A trial initiated in 2017 by the company recruited 24 patients with X-linked retinitis pigmentosa to undergo gene therapy.

Image credit: Pixabay